Headquartered in South San Francisco, CA Fiscal year ends December NASDAQ: GPCR structuretx.com
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule drugs for chronic metabolic diseases, with a focus on obesity. It uses a structure-based drug discovery platform targeting G protein-coupled receptors (GPCRs). Its wholly owned clinical-stage candidates are designed to avoid the scalability limits of biologic and peptide therapies.
Pipeline:
- Aleniglipron: its lead asset, a once-daily oral selective GLP-1 receptor agonist. It is in the Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 registrational trials for chronic weight management, including in patients with type 2 diabetes.
- ACCG-2671: an oral dual amylin and calcitonin receptor agonist (DACRA) in a Phase 1/2a multiple ascending dose study.
- ACCG-3535: a second DACRA candidate expected to enter Phase 1 in Q4 2026.
- Oral amylin/GLP-1 combination: a combination approach planned for clinical testing in 2027.
The company generates no product revenue. It funds operations from its cash and investment balance and is building commercial readiness plans for aleniglipron in initial weight loss and long-term weight maintenance. Updated
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether…
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX | VKTX Price Prediction) carries a 38.5% implied probability of being acquired before 2027,…
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Some of the best opportunities can still be found in obesity treatment stocks. Look at Viking Therapeutics (NASDAQ:VKTX | VKTX Price Prediction), for example. Now trading at $57.80, we strongly believe it…
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company that discovers and develops oral small molecule drugs for chronic metabolic diseases, with a focus on obesity. It uses a structure-based drug discovery platform targeting G protein-coupled receptors (GPCRs).
The Wall Street consensus 12-month price target for GPCR is $104.31.
